Related Experiment Video

Updated: Jul 7, 2026

An Improved Method to Isolate Mitochondrial Contact Sites
07:55

An Improved Method to Isolate Mitochondrial Contact Sites

Published on: June 16, 2023

Mitochondrial haplogroup H and Alzheimer's disease--is there a connection?

Aleksandra Maruszak1, Jeffrey A Canter, Maria Styczyńska

  • 1Department of Neurodegenerative Disorders, Polish Academy of Sciences Medical Research Center, 5 Pawińskiego Street, 02-106 Warsaw, Poland. ola.maruszak@cmdik.pan.pl

Neurobiology of Aging
|March 1, 2008
PubMed

Insights

Mitochondrial DNA haplogroup HV is linked to Alzheimer's disease (AD) risk in Poles, independent of APOE4 status. Further research into Haplogroup H subtypes is needed to clarify this association.

Area of Science:

  • Genetics
  • Neuroscience
  • Mitochondrial DNA research

Background:

  • Alzheimer's disease (AD) pathogenesis is complex, involving genetic factors.
  • Mitochondrial DNA (mtDNA) haplogroups, particularly Caucasian-specific ones, are investigated for their potential role in AD.
  • The interaction between mtDNA haplogroups and apolipoprotein E (APOE) genotype, a known AD risk factor, requires further elucidation.

Purpose of the Study:

  • To investigate the association of major Caucasian mtDNA haplogroups, clusters, and specific mitochondrial single nucleotide polymorphisms (mtSNPs) with Alzheimer's disease (AD) risk in the Polish population.
  • To explore the potential interplay between mtDNA haplogroups and APOE4 status in AD pathogenesis.
  • To clarify conflicting previous findings regarding specific mtDNA haplogroups and AD risk.

Main Methods:

  • Genotyping of Caucasian-specific mtDNA haplogroups (H, I, J, K, T, U, V, W, X) and haplogroup clusters (HV, UK, TJ, IWX) in a Polish cohort.
  • Analysis of two functional mtSNPs (4216, 4917).
  • Statistical analysis including chi-squared tests, logistic regression, and multivariate analysis to assess associations with AD and APOE4 status.

Main Results:

  • A significant non-random association was observed between mtDNA haplogroup distribution and APOE4 status (p<0.0001).
  • The HV mitochondrial DNA haplogroup cluster showed a significant association with increased Alzheimer's disease risk (OR=1.59, p=0.032), irrespective of APOE4 status.
  • No evidence was found supporting the involvement of mtDNA haplogroups U, K, J, or T in AD risk in this population, contrary to some prior studies.

Conclusions:

  • The HV mitochondrial DNA haplogroup cluster is a potential risk factor for Alzheimer's disease in the Polish population.
  • APOE4 status may modulate the influence of mtDNA haplogroups on AD risk.
  • Further investigation into the subtypes of Haplogroup H is warranted to fully understand the observed association with the HV cluster and AD.

More Related Videos

Using Live Cell STED Imaging to Visualize Mitochondrial Inner Membrane Ultrastructure in Neuronal Cell Models08:48

Using Live Cell STED Imaging to Visualize Mitochondrial Inner Membrane Ultrastructure in Neuronal Cell Models

Published on: June 30, 2023

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease09:38

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...